Merck Reports Three-Year KEYNOTE-177 Data for Keytruda in MSI-H Colorectal Cancer

Merck today presented three-year overall survival data from the Phase 3 KEYNOTE-177 trial evaluating Keytruda (pembrolizumab) as first-line treatment for patients with MSI-H/dMMR metastatic colorectal cancer. The data showed a significant improvement in overall survival with Keytruda, with a median overall survival not reached in the Keytruda arm compared to 36.7 months in the chemotherapy arm.